CN110150450A - 一种改善胆囊炎病症的特膳食品 - Google Patents
一种改善胆囊炎病症的特膳食品 Download PDFInfo
- Publication number
- CN110150450A CN110150450A CN201910530824.2A CN201910530824A CN110150450A CN 110150450 A CN110150450 A CN 110150450A CN 201910530824 A CN201910530824 A CN 201910530824A CN 110150450 A CN110150450 A CN 110150450A
- Authority
- CN
- China
- Prior art keywords
- parts
- cholecystitis
- illness
- special dietary
- fermentation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000005911 diet Nutrition 0.000 title claims abstract description 38
- 201000001352 cholecystitis Diseases 0.000 title claims abstract description 31
- 230000000378 dietary effect Effects 0.000 title claims abstract description 31
- 235000014102 seafood Nutrition 0.000 title claims abstract description 30
- 238000000855 fermentation Methods 0.000 claims abstract description 71
- 230000004151 fermentation Effects 0.000 claims abstract description 71
- 239000000843 powder Substances 0.000 claims abstract description 47
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 39
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 31
- 241000196324 Embryophyta Species 0.000 claims abstract description 27
- 244000068988 Glycine max Species 0.000 claims abstract description 26
- 239000002994 raw material Substances 0.000 claims abstract description 21
- 244000197580 Poria cocos Species 0.000 claims abstract description 18
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 18
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 16
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 16
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 16
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 16
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 241000894006 Bacteria Species 0.000 claims abstract description 15
- 229920001202 Inulin Polymers 0.000 claims abstract description 15
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 15
- 229940029339 inulin Drugs 0.000 claims abstract description 15
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 13
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 13
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims abstract description 10
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims abstract description 10
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract description 10
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims abstract description 10
- 239000007788 liquid Substances 0.000 claims description 29
- 238000005227 gel permeation chromatography Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 108091005508 Acid proteases Proteins 0.000 claims description 9
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 9
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 9
- 235000012054 meals Nutrition 0.000 claims description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 229920002774 Maltodextrin Polymers 0.000 claims description 5
- 239000005913 Maltodextrin Substances 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 5
- 239000000919 ceramic Substances 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 238000010612 desalination reaction Methods 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 229940035034 maltodextrin Drugs 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 230000035484 reaction time Effects 0.000 claims description 5
- 238000005352 clarification Methods 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims description 2
- 101800000263 Acidic protein Proteins 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 238000011049 filling Methods 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 6
- 239000004615 ingredient Substances 0.000 abstract description 5
- 108010038807 Oligopeptides Proteins 0.000 abstract 1
- 102000015636 Oligopeptides Human genes 0.000 abstract 1
- 238000002523 gelfiltration Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000011669 selenium Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 8
- 230000037213 diet Effects 0.000 description 7
- 238000005303 weighing Methods 0.000 description 6
- 210000000232 gallbladder Anatomy 0.000 description 5
- 244000046052 Phaseolus vulgaris Species 0.000 description 4
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 210000003445 biliary tract Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 3
- 235000011613 Pinus brutia Nutrition 0.000 description 3
- 241000018646 Pinus brutia Species 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 208000004845 Cholecystolithiasis Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000001883 cholelithiasis Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000008812 xiaoyanlidan Substances 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000000197 Acute Cholecystitis Diseases 0.000 description 1
- 241001106067 Atropa Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008614 Cholecystitis acute Diseases 0.000 description 1
- 206010008617 Cholecystitis chronic Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- JRFKIOFLCXKVOT-UHFFFAOYSA-N hydroxymethylnicotinamide Chemical compound OCNC(=O)C1=CC=CN=C1 JRFKIOFLCXKVOT-UHFFFAOYSA-N 0.000 description 1
- 229950005422 hydroxymethylnicotinamide Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/346—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
- A23L31/10—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种适合胆囊炎症病人食用的特膳食品制备方法,由植物发酵粉、大豆肽、罗伊氏乳杆菌、富硒酵母制备而成。其中植物发酵粉,是由松花粉、茯苓、山药、黄精、菊粉等原料,经嗜热链球菌、保加利亚乳杆菌等混合菌种进行发酵,并经喷雾干燥制备而成。大豆肽是酶解后通过凝胶过滤法收集得到特定分子量范围的低聚肽制备而成。将植物发酵粉、大豆肽,罗伊氏乳杆菌、富硒酵母等成分,按照比例混合、灌装,制备成为特膳食品。本发明的特膳食品不仅成本低、口感好,能够很好适合胆囊炎病人使用,经人群试用,具有较好的预防作用;此外,该特膳食品在制备过程中,易灌装,澄清度高、稳定性好,操作食用方便。
Description
技术领域
本发明属于特膳食品领域,尤其涉及一种改善胆囊炎病症的特膳食品。
背景技术
胆道系统包括肝内胆道和肝外胆道两部分,具有分泌、浓缩、贮存、输送胆汁与胆汁代谢的作用,其发育异常及胆汁酸代谢异常与临床胆道疾病的发生密切相关。胆囊炎是胆道疾病中最常见的一种病症,今年来,随着人们饮食结构的改变,胆囊炎的发病日益增多,并逐年上身趋势,目前我国成年人胆囊结石伴胆囊炎的发病率为10%,中年妇女甚至高达15%。无论是胆囊结石,还是其他如致病菌引起的胆囊炎症,其囊壁总会存在一定程度的充血、水肿、渗出,或者坏死和纤维增生等炎性改变,这些改变会使得病人疼痛难忍,往往可并发抑郁。
目前对于胆囊炎轻症患者,可采取保守的非手术治疗,低脂饮食,长期口服利胆药物,如消炎利胆片、熊胆胶囊、利胆素等,腹痛时可用颠茄类解痉药物对症治疗,必要时抗感染治疗。而对于患者症状重的反复发作胆绞痛,伴有胆囊结石者应选择手术治疗。
病人日常饮食不当可诱发并加重胆囊炎的发病,不利于疾病的恢复,所以患有胆囊炎的人一定要调整好饮食,为更好的恢复机体,实现人体免疫机能的提高,慢性胆囊炎患者,应多服用一些含脂肪低的高生物价优质蛋白食物、碳水化合物、膳食纤维等食品来源,从日常饮食中进行控制。因此,在日常饮食和术后护养中,应适当补充一定营养特膳食品,确保机体尽快恢复。
发明内容
本发明针对现有技术的不足,提供一种改善胆囊炎病症的特膳食品。
本发明的目的在于提供一种改善胆囊炎病症的特膳食品,其组分按照重量份数包括:植物发酵粉30~40份、大豆肽20~30份、罗伊氏乳杆菌5~10份和富硒酵母5~10份;富硒酵母中总硒含量为1000~2500mg/kg。
所述植物发酵粉是由松花粉20~30份、茯苓15~20份、山药10~20份、黄精10~20份、菊粉10~20份发酵制备而成;所述大豆肽是采用凝胶层析法制备而成。
优选的,所述植物发酵粉,其制备方法包括如下步骤:
(1)混合:按照松花粉20~30份、茯苓15~20份、山药10~20份、黄精10~20份、菊粉10~20份称取原料,并将所述茯苓、山药、黄精分别投入万能粉碎机内粉碎,然后通过80~100目筛网,并与松花粉、菊粉混合均匀;
(2)发酵:将混合好的原料,与水按照质量比1:10~1:20混匀,浸泡12~24h,拌入乳酸菌,倒入发酵罐中,形成发酵液;对所述发酵液进行超声发酵处理,期间每隔12h~24h搅拌一次发酵液,使其混合均匀,发酵周期为5~10天;发酵结束后,将发酵液离心澄清,并按照发酵液30~50wt%比例加入麦芽糊精,经喷雾干燥制备得到植物发酵粉。
其中,所述乳酸菌为嗜热链球菌与保加利亚乳杆菌。
其中,所述嗜热链球菌的菌落含量占发酵液体积5.5~8.5×105CFU/mL,所述保加利亚乳杆菌的菌落含量占发酵液体积6.5~9.5×105CFU/mL。
其中,所述超声发酵处理,其超声频率为15Hz~35Hz。
其中,所述离心澄清采用高速管式离心机实现。
优选的,所述大豆肽,其制备方法包括如下步骤:
(1)酶解:将大豆粉经蛋白酶酶解并脱盐,陶瓷膜过滤并冷冻干燥,获得酶解冻干粉;
(2)纯化:将酶解冻干粉复溶,经凝胶过滤层析柱过滤,获得1000Da以下大豆肽,再次经冻干获得大豆肽粉。
其中,步骤(1)中所述蛋白酶酶解,其工作条件为:为大豆粉与水质量比为1:5~1:10,制备混合溶液,并加入酸性蛋白酶,酶活达到4000U/g~6000U/g,其中酸性蛋白酶和大豆粉质量比为1:10~1:500,反应温度25~75℃,反应时间为10~24h,pH值为2~4。
其中,所述凝胶过滤层析柱过滤后,获得大豆肽分子量为500Da以下。
优选的,所述茯苓、山药、黄精,其水分含量不超过5wt%。
所述的产品混合制备方法如下:
将植物发酵粉30~40份、大豆肽20~30份、罗伊氏乳杆菌5~10份、富硒酵母5~10份,进行混合灌装,制备出特膳食品,并根据口感加入适量的甜味剂1~5份。
本发明的使用方法为:本发明特膳食品的食用量为10~20g/天。
本发明的有益效果为:本发明提供了一种用于适合胆囊炎症病人食用的特膳食品,通过多种药食同源原料与现代精制原料复配,能够很好补充胆囊炎病患的日常饮食营养需求,也是理想的辅助治疗特膳食品。与传统营养膳食相比,本发明具有含量活性成分高、易吸收、配料科学、功效显著、无副作用等诸多健康优点。
具体实施方式
以下结合实例对本发明的原理和特征进行描述,所举实例只用于解释本发明,并非用于限定本发明的范围。
本发明实施例中使用罗伊氏乳杆菌由诺维信(中国)生物科技有限公司提供,富硒酵母由安琪酵母股份有限公司提供,酸性蛋白酶由东恒华道生物科技有限责任公司提供。罗伊氏乳杆菌的菌活为1×1010CFU/g~1×1012CFU/g,富硒酵母中总硒含量为1000~2500mg/kg,酸性蛋白酶酶活为20000~50000U/g。
实施例1
一种改善胆囊炎病症的特膳食品,其组分按照重量份数包括:植物发酵粉30份、大豆肽20份、罗伊氏乳杆菌10份、富硒酵母10份;其中植物发酵粉是由松花粉30份、茯苓20份、山药20份、黄精10份、菊粉10份发酵制备而成;大豆肽是采用凝胶层析法制备而成。
所述的植物发酵粉制备如下:
(1)混合:按照松花粉30份、茯苓20份、山药20份、黄精10份、菊粉10份,称取原料,并将所述茯苓、山药、黄精分别投入万能粉碎机内粉碎,粉碎原料应通过80目筛网,并与松花粉、菊粉进行均匀;
(2)发酵:将混合好的原料与水按照质量比1:10混匀,浸泡12h,拌入嗜热链球菌、保加利亚乳杆菌,倒入发酵罐中,形成发酵液;原料中嗜热链球菌的菌落含量为8.5×105CFU/mL,保加利亚乳杆菌菌落含量为9.5×105CFU/mL;将上述发酵液进行超声发酵处理,超声频率35Hz,期间每隔12h搅拌一次发酵液,使其混合均匀,共发酵周期为5天,发酵液采用高速管式离心机澄清,并按照发酵液50wt%比例加入麦芽糊精,经喷雾干燥制备得到植物发酵粉。
所述的大豆肽制备方法如下:
(1)酶解:称取大豆粉原料与水,按照质量比1:5进行配比,制备混合溶液,并加入酸性蛋白酶,,其中酸性蛋白酶和大豆粉(干质)的质量比为1:10,反应温度25℃,反应时间为10h,PH值为2.5,经脱盐后,陶瓷膜过滤以及冷冻干燥,获得酶解冻干粉。
(2)纯化:将酶解冻干粉复溶,经凝胶过滤层析柱过滤,收集分子量1000Da以下的成分,再次经冻干获得大豆肽粉。
所述的产品混合制备方法如下:
将植物发酵粉30份、大豆肽20份、罗伊氏乳杆菌10份、富硒酵母10份,进行混合灌装,制备出特膳食品,并根据口感加入适量的甜味剂5份。
实施例2
一种改善胆囊炎病症的特膳食品,其组分按照重量份数包括:植物发酵粉35份、大豆肽25份、罗伊氏乳杆菌8份、富硒酵母8份;其中植物发酵粉是由松花粉25份、茯苓18份、山药15份、黄精15份、菊粉15份发酵制备而成;大豆肽是采用凝胶层析法制备而成。
所述的植物发酵粉制备方法如下:
(1)混合:按照松花粉25份、茯苓18份、山药15份、黄精15份、菊粉15份,称取原料,并将所述茯苓、山药、黄精分别投入万能粉碎机内粉碎,粉碎原料应通过80目筛网,并与松花粉、菊粉进行均匀;
(2)发酵:将混合好的原料,与水按照质量比1:15混匀,浸泡18h,拌入嗜热链球菌、保加利亚乳杆菌,倒入发酵罐中,形成发酵液;原料中嗜热链球菌的菌落含量为5.5×105CFU/mL,保加利亚乳杆菌的菌落含量为6.5×105CFU/mL;将上述发酵液进行超声发酵处理,超声频率15Hz,期间每隔18h搅拌一次发酵液,使其混合均匀,共发酵周期为7天,发酵液采用高速管式离心机澄清,并按照发酵液30wt%比例加入麦芽糊精,经喷雾干燥制备得到植物发酵粉。
所述的大豆肽制备方法如下:
(1)酶解:称取大豆粉原料与水,按照质量比1:8进行配比,制备混合溶液,并加入酸性蛋白酶,其中蛋白酶和大豆粉(干质)的质量比为1:200,反应温度50℃,反应时间为20h,PH值为3.5经脱盐后,陶瓷膜过滤以及冷冻干燥,获得酶解冻干粉。
(2)纯化:将酶解冻干粉,复溶,经凝胶过滤层析柱过滤,收集分子量800Da以下的成分,再次经冻干获得大豆肽粉。
所述的产品混合制备方法如下:
将植物发酵粉35份、大豆肽25份、罗伊氏乳杆菌8份、富硒酵母8份,进行混合灌装,制备出特膳食品,并根据口感加入适量的甜味剂2份。
实施例3
一种改善胆囊炎病症的特膳食品,其组分按照重量份数包括:植物发酵粉40份、大豆肽30份、罗伊氏乳杆菌5份、富硒酵母5份;其中植物发酵粉是由松花粉20份、茯苓15份、山药10份、黄精20份、菊粉20份发酵制备而成;大豆肽是采用凝胶层析法制备而成。
所述的植物发酵粉制备方法如下:
(1)混合:按照松花粉20份、茯苓15份、山药10份、黄精20份、菊粉20份,称取原料,并将所述茯苓、山药、黄精分别投入万能粉碎机内粉碎,粉碎原料应通过100目筛网,并与松花粉、菊粉进行均匀;
(2)发酵:将混合好的原料与水按照质量比1:20混匀,浸泡24h,拌入嗜热链球菌、保加利亚乳杆菌,倒入发酵罐中,形成发酵液;原料中嗜热链球菌的菌落含量为7.0×105CFU/mL,保加利亚乳杆菌的菌落含量为8.0×105CFU/mL;将上述发酵液进行超声发酵处理,超声频率25Hz,期间每隔24h搅拌一次发酵液,使其混合均匀,共发酵周期为10天,发酵液采用高速管式离心机澄清,并按照发酵液40wt%比例加入麦芽糊精,经喷雾干燥制备得到植物发酵粉。
所述的大豆肽制备方法如下:
(1)酶解:称取大豆粉原料与水,按照质量比1:10进行配比,制备混合溶液,并加入酸性蛋白酶,其中蛋白酶和大豆粉(干质)的质量比为1:500,反应温度75℃,反应时间为24h,PH值为4,经脱盐后,陶瓷膜过滤以及冷冻干燥,获得酶解冻干粉。
(2)纯化:将酶解冻干粉,复溶,经凝胶过滤层析柱过滤,收集分子量500Da以下的成分,再次经冻干获得大豆肽粉。
所述的产品混合制备方法如下:
将植物发酵粉40份、大豆肽30份、罗伊氏乳杆菌5份、富硒酵母5份,进行混合灌装,制备出特膳食品,并根据口感加入适量的甜味剂1份.
实验例
设计动物实验以证明本发明的有益效果。
方法:取3~4月龄雄性豚鼠,260±300g,54只,共6组,每组9只。分为:空白对照组、模型组、阳性药物组、高剂量组、中剂量组和低剂量组。除空白组外,均通过注射大肠杆菌建立急性胆囊炎豚鼠模型。模型成功后,开始服用特膳品。空白对照组与模型灌胃生理盐水,阳性组给予消炎利胆片0.35g/kg,高剂量25g/kg,中剂量组20g/kg,低剂量组10g/kg,连续服用30d,检测:①身体体重、评估运动情况;②、检测血清和胆汁中TNF-α、IL-6;③胆囊及肝脏重量,统计肝指数和胆囊指数。
结果:模型组服用本产品后,体重较模型组体重增加(P<0.05,P<0.01),其各剂量影响干预的模型组,其老鼠活动频率较高,与空白组相当,而模型组整体状态不好;肝指数与胆囊指数均一定程度的降低。各剂量组与模型组相比,血清和胆汁中TNF-α、IL-6等胆汁水平明显降低。
结论:本产品可以改善并减轻胆囊炎症的模型动物的炎症反应,并能够很好的改善模型鼠的活动情况。
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种改善胆囊炎病症的特膳食品,其特征在于其组分按照重量份数包括:植物发酵粉30~40份、大豆肽20~30份、罗伊氏乳杆菌5~10份和富硒酵母5~10份;所述富硒酵母中总硒含量为1000~2500mg/kg;
所述植物发酵粉是由松花粉20~30份、茯苓15~20份、山药10~20份、黄精10~20份、菊粉10~20份发酵制备而成;所述大豆肽是采用凝胶层析法制备而成。
2.根据权利要求1所述的改善胆囊炎病症的特膳食品,其特征在于,所述植物发酵粉,其制备方法包括如下步骤:
(1)混合:按照松花粉20~30份、茯苓15~20份、山药10~20份、黄精10~20份、菊粉10~20份称取原料,并将所述茯苓、山药、黄精分别投入万能粉碎机内粉碎,然后通过80~100目筛网,并与松花粉、菊粉混合均匀;
(2)发酵:将混合好的原料与水按照质量比1:10~1:20混匀,浸泡12~24h,拌入乳酸菌,倒入发酵罐中,形成发酵液;对所述发酵液进行超声发酵处理,期间每隔12h~24h搅拌一次发酵液,使其混合均匀,发酵周期为5~10天;发酵结束后,将发酵液离心澄清,并按照发酵液30~50wt%比例加入麦芽糊精,经喷雾干燥制备得到植物发酵粉。
3.根据权利要求2所述的改善胆囊炎病症的特膳食品,其特征在于,所述乳酸菌为嗜热链球菌与保加利亚乳杆菌。
4.根据权利要求3所述的改善胆囊炎病症的特膳食品,其特征在于,所述嗜热链球菌的菌落含量占发酵液体积5.5~8.5×105CFU/mL,所述保加利亚乳杆菌的菌落含量占发酵液体积6.5~9.5×105CFU/mL。
5.根据权利要求2所述的改善胆囊炎病症的特膳食品,其特征在于,所述超声发酵处理,其超声频率为15Hz~35Hz。
6.根据权利要求2所述的改善胆囊炎病症的特膳食品,其特征在于,所述离心澄清采用高速管式离心机实现。
7.根据权利要求1所述的改善胆囊炎病症的特膳食品,其特征在于,所述大豆肽,其制备方法包括如下步骤:
(1)酶解:将大豆粉经蛋白酶酶解并脱盐,陶瓷膜过滤并冷冻干燥,获得酶解冻干粉;
(2)纯化:将酶解冻干粉复溶,经凝胶过滤层析柱过滤,获得1000Da以下大豆肽,再次经冻干获得大豆肽粉。
8.根据权利要求7所述的改善胆囊炎病症的特膳食品,其特征在于,步骤(1)中所述蛋白酶酶解,其工作条件为:大豆粉与水质量比为1:5~1:10,制备混合溶液,并加入酸性蛋白酶,其中酸性蛋白酶和大豆粉质量比为1:10~1:500,反应温度25~75℃,反应时间为10~24h,pH值为2~4。
9.根据权利要求7所述的改善胆囊炎病症的特膳食品,其特征在于,所述凝胶过滤层析柱过滤后,获得大豆肽分子量为500Da以下。
10.根据权利要求1所述的改善胆囊炎病症的特膳食品,其特征在于,所述茯苓、山药、黄精,其水分含量不超过5wt%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910530824.2A CN110150450A (zh) | 2019-06-19 | 2019-06-19 | 一种改善胆囊炎病症的特膳食品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910530824.2A CN110150450A (zh) | 2019-06-19 | 2019-06-19 | 一种改善胆囊炎病症的特膳食品 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110150450A true CN110150450A (zh) | 2019-08-23 |
Family
ID=67625994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910530824.2A Pending CN110150450A (zh) | 2019-06-19 | 2019-06-19 | 一种改善胆囊炎病症的特膳食品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110150450A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103844266A (zh) * | 2014-03-25 | 2014-06-11 | 容瑜 | 一种天然调理养生酵素及其制造方法 |
CN104223087A (zh) * | 2014-09-30 | 2014-12-24 | 胡安然 | 胆囊炎、胆结石全营养配方食品 |
CN105029401A (zh) * | 2015-04-11 | 2015-11-11 | 劲膳美生物科技股份有限公司 | 胆囊炎、胆结石医学配方食品 |
WO2016045310A1 (zh) * | 2014-09-25 | 2016-03-31 | 容瑜 | 溶石酵素 |
CN106107998A (zh) * | 2016-08-26 | 2016-11-16 | 陈锷 | 一种中药复合酵素及其制备方法 |
CN109221898A (zh) * | 2018-06-04 | 2019-01-18 | 山东龙力生物科技股份有限公司 | 一种含低聚木糖的谷物粉及其制备方法和应用 |
-
2019
- 2019-06-19 CN CN201910530824.2A patent/CN110150450A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103844266A (zh) * | 2014-03-25 | 2014-06-11 | 容瑜 | 一种天然调理养生酵素及其制造方法 |
WO2016045310A1 (zh) * | 2014-09-25 | 2016-03-31 | 容瑜 | 溶石酵素 |
CN104223087A (zh) * | 2014-09-30 | 2014-12-24 | 胡安然 | 胆囊炎、胆结石全营养配方食品 |
CN105029401A (zh) * | 2015-04-11 | 2015-11-11 | 劲膳美生物科技股份有限公司 | 胆囊炎、胆结石医学配方食品 |
CN106107998A (zh) * | 2016-08-26 | 2016-11-16 | 陈锷 | 一种中药复合酵素及其制备方法 |
CN109221898A (zh) * | 2018-06-04 | 2019-01-18 | 山东龙力生物科技股份有限公司 | 一种含低聚木糖的谷物粉及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
谢文佩等: "食品酵素加工工艺研究进展", 《现代农业科技》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113332354B (zh) | 一种抗糖化抗衰老发酵组合物及其制备方法 | |
CN107348521B (zh) | 具有改善胃肠道功能的中药复合肽组合物及其制备方法 | |
CN106798252A (zh) | 一种具有调理肠胃降血脂溶血栓功效的纳豆组方 | |
CN106954843A (zh) | 一种复合植物酵素原液、功能性复合植物酵素原液及其制备方法和功能性食品 | |
CN101238893B (zh) | 一种高膳食纤维鹰嘴豆营养粉及其制备方法和用途 | |
GB2589967A (en) | Chinese yellow rice wine containing ingredients of mulberry leaves (morus alba L.) and silkworm pupae (bombyx mori) and production method thereof | |
CN109907221A (zh) | 一种具有抗氧化杂粮营养面粉以及制备方法 | |
CN103181520A (zh) | 一种铁皮石斛乳酸菌胶囊的制备方法 | |
CN117089580B (zh) | 干酪乳杆菌sf-l-12发酵物及其制备工艺、应用 | |
CN101099844A (zh) | 健脾益肾制剂的配方以及制备方法 | |
CN110140879A (zh) | 一种富含益生菌的杂粮粉及其制备方法 | |
CN110150450A (zh) | 一种改善胆囊炎病症的特膳食品 | |
KR20110118911A (ko) | 한약재를 이용한 유산균 곡물 발효 추출물 및 이의 제조방법 | |
CN1788578A (zh) | 一种微米松花魔芋露减肥降糖酸豆奶制备方法 | |
CN113144167A (zh) | 一种具有降尿酸效果的发酵型小分子肽混合液及其制备方法和应用 | |
CN105343550A (zh) | 一种用于治疗眼病的制剂制备方法及其制剂 | |
CN111528471A (zh) | 一种具有减肥功能的植物益生菌发酵物及其制备方法和用途 | |
CN116898952B (zh) | 一种健脾利湿、化痰涤饮功效的泽泻汤及制备方法 | |
CN115606727B (zh) | 功能糖与羊乳清蛋白复合的微生态制剂、制备方法及应用 | |
CN110904022B (zh) | 芽孢杆菌培养基及其在肠胃调理奶粉上的应用 | |
CN115487234A (zh) | 一种具有降血脂作用的组合物、益生菌饮料及其制备方法 | |
CN106172653A (zh) | 一种富含花青素的山药陈皮糕 | |
CN118285503A (zh) | 加味四神膏的制备、产品及其应用 | |
CN113508904A (zh) | 一种具有降脂功能的复方发酵液的制备方法 | |
CN114668144A (zh) | 一种降糖复合植物酵素、制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190823 |